Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Si­lence Ther­a­peu­tics has re­port­ed its siR­NA drug can­di­date showed pos­i­tive re­sults in a mid-stage test of pa­tients with high low-den­si­ty lipopro­tein at risk of car­dio­vas­cu­lar events, hit­ting bench­marks set by some an­a­lysts.

The UK biotech al­so re­port­ed Wednes­day that Mallinck­rodt de­cid­ed to stop fur­ther de­vel­op­ment of com­ple­ment C3-tar­get­ing drug SLN501 af­ter Phase I com­ple­tion, ef­fec­tive­ly end­ing their part­ner­ship, ac­cord­ing to a sep­a­rate full-year earn­ings re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER